microRNA 4295 (MIR4295)

microRNA 4295 (MIR4295) is a non-coding RNA located on chromosome 10q25.2, processed from the intron of the VTI1A gene. It regulates gene expression by binding to complementary sequences in target mRNAs, typically leading to translational repression or mRNA degradation. MIR4295 is implicated in diverse cellular processes including proliferation, apoptosis, migration, and the epithelial–mesenchymal transition, especially in the context of cancer. Its aberrant expression has been observed in prostate, bladder, gastric, glioma, and osteosarcoma tissues, where it may serve diagnostic and prognostic functions. MIR4295 interacts with a network of targets such as TP63, CDKN1A, BTG1, RUNX3, IRF1, and is modulated by therapeutic agents like ginsenoside Rh2 and propranolol, underscoring its importance as both a biomarker and a potential therapeutic target.

Other names

MIR4295hsa-mir-4295mir-4295miR-4295miR4295

Drugs may act by upregulating or downregulating miR-4295, altering expression of key target genes (e.g., affecting cell proliferation, migration, EMT). Propranolol lowers miR-4295, associating with anti-angiogenic and tumor-suppressing effects. Ginsenoside Rh2 reduces miR-4295 to slow cancer cell proliferation.